Neupulse Raises £500k to Develop Tourette's Syndrome Device
Neupulse Raises £500K in Seed Follow On Funding
Neupulse Secures £500k in Equity Funding
Neupulse (Linkedin), a University of Nottingham spinout, has raised £500k to further develop their innovative wristband device for managing symptoms of Tourette's syndrome. With a 25% reduction in tic frequency during initial trials, Neupulse aims to target individuals suffering from Tourette's syndrome, healthcare providers specializing in movement disorders, and patient advocacy groups.
Funding Amount: £500k
Industry: Hospitals and Health Care
Employee Count: 2-10
CEO: Paul Cable (CEO Linkedin)
What Neupulse needs to buy: Neupulse is seeking clinical research partnerships, regulatory consulting services, and marketing and outreach services to support the development, regulatory approval, and promotion of their wristband device for Tourette's syndrome. Companies specializing in clinical research, regulatory consulting, and healthcare marketing can explore collaboration opportunities with Neupulse to help bring their innovative solution to market.